Basic Information
Fampridine Accord
Regulatory Information
EMEA/H/C/005359
September 24, 2020
July 23, 2020
4
April 11, 2024
Company Information
Spain
Edificio Este Planta 6a World Trade Center Moll De Barcelona S/n 08039 Barcelona
ACCORD HEALTHCARE SL
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Fampridine Accord is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4-7).
Overview Summary
Fampridine Accord is a medicine used to improve walking ability in adults with multiple sclerosis (MS) who have a walking disability. MS is a disease in which the immune system (the body’s defences) attacks and damages the covering around the nerves and the nerves themselves in the brain and spinal cord. Fampridine Accord is a ‘generic medicine’. This means that Fampridine Accord contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Fampyra. For more information on generic medicines, see the question-and-answer document below. Fampridine Accord contains the active substance fampridine.